Financials Pacific Shuanglin Bio-pharmacy Co., LTD

Equities

000403

CNE000000F14

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
27.31 ^CNY	-0.36%		-5.34%	+0.26%

May. 09	Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License	MT
Apr. 26	Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	8,804	18,713	20,540	16,669	19,957	19,959	-	-
Enterprise Value (EV) ¹	8,804	18,713	20,540	16,669	19,957	19,959	19,959	19,959
P/E ratio	54.9 x	100 x	50.7 x	28.3 x	32.5 x	25.5 x	22.5 x	18.6 x
Yield	0.37%	-	0.2%	-	0.73%	0.95%	0.77%	1.28%
Capitalization / Revenue	9.62 x	17.8 x	10.4 x	6.93 x	8.57 x	6.5 x	5.77 x	4.96 x
EV / Revenue	9.62 x	17.8 x	10.4 x	6.93 x	8.57 x	6.5 x	5.77 x	4.96 x
EV / EBITDA	-	-	-	21.2 x	24 x	21.2 x	18.5 x	15.9 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	11 x	19.4 x	3.25 x	2.43 x	2.69 x	2.48 x	2.26 x	2.05 x
Nbr of stocks (in thousands)	489,218	492,435	732,783	732,360	732,646	730,818	-	-
Reference price ²	18.00	38.00	28.03	22.76	27.24	27.31	27.31	27.31
Announcement Date	3/17/20	3/23/21	4/15/22	4/28/23	4/13/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	915.7	1,050	1,972	2,405	2,329	3,072	3,458	4,024
EBITDA ¹	-	-	-	785.5	832.8	941	1,077	1,256
EBIT ¹	180	220.3	460.4	663.4	695.2	905.5	1,015	1,241
Operating Margin	19.66%	20.98%	23.35%	27.58%	29.85%	29.48%	29.34%	30.84%
Earnings before Tax (EBT) ¹	189	217.2	458	660.4	688.1	900.5	1,012	1,236
Net income ¹	160.4	186	391.1	587.1	612.1	784	889.5	1,076
Net margin	17.52%	17.71%	19.83%	24.41%	26.29%	25.52%	25.72%	26.74%
EPS ²	0.3280	0.3793	0.5530	0.8032	0.8384	1.070	1.215	1.470
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	0.0674	-	0.0560	-	0.2000	0.2600	0.2100	0.3500
Announcement Date	3/17/20	3/23/21	4/15/22	4/28/23	4/13/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2024 Q1
Net sales ¹	435.6
EBITDA	-
EBIT	-
Operating Margin	-
Earnings before Tax (EBT)	-
Net income ¹	121.9
Net margin	27.99%
EPS	-
Dividend per Share	-
Announcement Date	4/26/24

¹CNY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	22.3%	21.2%	7.04%	8.9%	8.58%	9.7%	10%	11%
ROA (Net income/ Total Assets)	-	-	-	7.36%	-	8.6%	9.07%	9.8%
Assets ¹	-	-	-	7,982	-	9,116	9,811	10,980
Book Value Per Share ²	1.640	1.960	8.630	9.380	10.10	11.00	12.10	13.40
Cash Flow per Share ²	0.3900	0.4000	0.5600	-	0.9300	0.6100	1.590	1.560
Capex ¹	41.1	40.1	325	378	376	131	150	129
Capex / Sales	4.49%	3.82%	16.47%	15.72%	16.13%	4.26%	4.33%	3.21%
Announcement Date	3/17/20	3/23/21	4/15/22	4/28/23	4/13/24	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Pacific Shuanglin Bio-pharmacy Co., LTD

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.31 CNY

Average target price

37 CNY

Spread / Average Target

+35.48%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD	+0.26%	2.76B
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B

Biopharmaceuticals